Co-Diagnostics Files to Sell 4.94M Shares of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 28 2026
0mins
Co-Diagnostics files to sell 4.94M shares of common stock for holders
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CODX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CODX
Wall Street analysts forecast CODX stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 4.700
Low
1.50
Averages
1.50
High
1.50
Current: 4.700
Low
1.50
Averages
1.50
High
1.50
About CODX
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SciSparc Receives Approval to Acquire Stake in Israeli Tech Firm
- Acquisition Approval: SciSparc Ltd. (SPRC) received regulatory approval from the TSX Venture Exchange for its subsidiary NeuroThera Labs to acquire approximately 54% of CliniQuantum, valued at about $9.46 million, which is expected to enhance its competitive edge in clinical trial data analysis.
- Stock Surge: SPRC's shares soared nearly 140% to close at $10.55 on Thursday, reflecting strong market enthusiasm for its acquisition plans, which may attract further investor interest in its future growth prospects.
- Ebola Testing Progress: Co-Diagnostics Inc. (CODX) saw its stock rally over 50% for the third consecutive day amid the Ebola outbreak, indicating the effectiveness of its PCR assay strategy, which is likely to bolster the company's influence in public health.
- Clinical Trial Initiation: MiNK Therapeutics (INKT) dosed its first patient in a randomized phase 2 trial for acute lung injury, leading to an 18% stock increase, and this advancement could provide crucial data support for its future treatment options, strengthening its market position.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Significant Pre-Market Gains: Wellgistics Health, Inc. (WGRX) surged 29% to $4.05 in pre-market trading, indicating strong market confidence in its future growth, which may attract more investor interest.
- Other Gainers: Co-Diagnostics, Inc. (CODX) rose 11% to $8.12, while Palladyne AI Corp. (PDYN) increased 10% to $8.21, reflecting an overall positive sentiment in the biotech sector that could drive investment momentum.
- Pre-Market Decliners: AIM ImmunoTech Inc. (AIM) fell 21% to $0.32, highlighting market concerns about its outlook, which may lead investors to reassess their strategies.
- Additional Decliners: BioRestorative Therapies, Inc. (BRTX) dropped 20% to $1.30, and Aditxt, Inc. (ADTX) decreased 18% to $0.17, indicating a lack of confidence in certain biotech companies, potentially impacting their fundraising capabilities.
See More
Co-Diagnostics (CODX) Q4 2025 Earnings Transcript
See More
Multiple Companies See Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw its stock price jump nearly 80% to $9.11 on Tuesday as it advances the development of its Ebola PCR assay, which is expected to significantly enhance the company's competitiveness in the molecular diagnostics market.
- NRXP Regulatory Catalysts: NRx Pharmaceuticals Inc. (NRXP) shares rose over 30% to $4.31, driven by the anticipation of a New Drug Application submission to the FDA, which is expected to boost the company's market share in the treatment of suicidal depression.
- ECOR Revenue Growth: electroCore Inc. (ECOR) reported a 43% revenue increase in Q1, with expectations of a 30% rise in annual revenue compared to 2025, leading to a 33.58% stock price increase, indicating strong performance in the bioelectronic medicine sector.
- OTLK Regulatory Progress: Outlook Therapeutics Inc. (OTLK) shares jumped over 29% to $0.40 following positive regulatory developments regarding LYTENAVA, with plans to resubmit the Biologics License Application in June 2026, reflecting a strategic shift in their approach to FDA engagement.
See More
U.S. Stocks Rise Slightly, Nasdaq Hits Record High
- Market Recovery: The S&P 500 rose 0.6% to close at 7,519.12, while the Nasdaq gained 1.2% to 26,656.18, indicating increased investor confidence in U.S. equities, particularly amid positive developments in peace talks with Iran.
- Small-Cap Surge: The Russell 2000 index climbed 1.8% to reach a record high, marking its fourth consecutive day of gains, reflecting optimistic sentiment towards small-cap stocks likely driven by expectations of economic recovery.
- Tech Stocks Lead Gains: Micron Technology's stock surged after UBS raised its price target to $1,625, significantly boosting overall tech sector performance and reinforcing strong investor confidence in the technology industry.
- Oil Market Volatility: Despite military exchanges between the U.S. and Iran raising concerns, West Texas Intermediate crude futures fell 2.81% to $93.89 per barrel, while Brent crude rose 3.58% to $99.58, illustrating the market's complex reactions to energy prices.
See More
Co-Diagnostics Partners with Indian JV to Tackle Ebola Outbreak
- Stock Surge: Co-Diagnostics (CODX) shares soared nearly 80% on Tuesday, extending a blistering six-session rally that has seen the stock rise over 630%, reflecting strong market demand for diagnostics amid growing Ebola outbreak concerns.
- International Deployment Plan: The company is collaborating with its Indian joint venture, CoSara Diagnostics, to expedite international deployment in response to the potential global spread of the Ebola outbreak, highlighting its proactive role in emergency response efforts.
- Testing Technology Development: Co-Diagnostics is developing a PCR test targeting the Bundibugyo virus strain, with plans to introduce both Bundibugyo-specific and pan-Ebola test configurations to enhance monitoring capabilities for the outbreak.
- Global Health Emergency: The World Health Organization has declared the outbreak a public health emergency of international concern, with over 900 suspected cases and 223 suspected deaths reported, underscoring the severity of the situation and its threat to global health.
See More
SciSparc Receives Approval to Acquire Stake in Israeli Tech Firm
- Acquisition Approval: SciSparc Ltd. (SPRC) received regulatory approval from the TSX Venture Exchange for its subsidiary NeuroThera Labs to acquire approximately 54% of CliniQuantum, valued at about $9.46 million, which is expected to enhance its competitive edge in clinical trial data analysis.
- Stock Surge: SPRC's shares soared nearly 140% to close at $10.55 on Thursday, reflecting strong market enthusiasm for its acquisition plans, which may attract further investor interest in its future growth prospects.
- Ebola Testing Progress: Co-Diagnostics Inc. (CODX) saw its stock rally over 50% for the third consecutive day amid the Ebola outbreak, indicating the effectiveness of its PCR assay strategy, which is likely to bolster the company's influence in public health.
- Clinical Trial Initiation: MiNK Therapeutics (INKT) dosed its first patient in a randomized phase 2 trial for acute lung injury, leading to an 18% stock increase, and this advancement could provide crucial data support for its future treatment options, strengthening its market position.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Significant Pre-Market Gains: Wellgistics Health, Inc. (WGRX) surged 29% to $4.05 in pre-market trading, indicating strong market confidence in its future growth, which may attract more investor interest.
- Other Gainers: Co-Diagnostics, Inc. (CODX) rose 11% to $8.12, while Palladyne AI Corp. (PDYN) increased 10% to $8.21, reflecting an overall positive sentiment in the biotech sector that could drive investment momentum.
- Pre-Market Decliners: AIM ImmunoTech Inc. (AIM) fell 21% to $0.32, highlighting market concerns about its outlook, which may lead investors to reassess their strategies.
- Additional Decliners: BioRestorative Therapies, Inc. (BRTX) dropped 20% to $1.30, and Aditxt, Inc. (ADTX) decreased 18% to $0.17, indicating a lack of confidence in certain biotech companies, potentially impacting their fundraising capabilities.
See More
Co-Diagnostics (CODX) Q4 2025 Earnings Transcript
See More
Multiple Companies See Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw its stock price jump nearly 80% to $9.11 on Tuesday as it advances the development of its Ebola PCR assay, which is expected to significantly enhance the company's competitiveness in the molecular diagnostics market.
- NRXP Regulatory Catalysts: NRx Pharmaceuticals Inc. (NRXP) shares rose over 30% to $4.31, driven by the anticipation of a New Drug Application submission to the FDA, which is expected to boost the company's market share in the treatment of suicidal depression.
- ECOR Revenue Growth: electroCore Inc. (ECOR) reported a 43% revenue increase in Q1, with expectations of a 30% rise in annual revenue compared to 2025, leading to a 33.58% stock price increase, indicating strong performance in the bioelectronic medicine sector.
- OTLK Regulatory Progress: Outlook Therapeutics Inc. (OTLK) shares jumped over 29% to $0.40 following positive regulatory developments regarding LYTENAVA, with plans to resubmit the Biologics License Application in June 2026, reflecting a strategic shift in their approach to FDA engagement.
See More
U.S. Stocks Rise Slightly, Nasdaq Hits Record High
- Market Recovery: The S&P 500 rose 0.6% to close at 7,519.12, while the Nasdaq gained 1.2% to 26,656.18, indicating increased investor confidence in U.S. equities, particularly amid positive developments in peace talks with Iran.
- Small-Cap Surge: The Russell 2000 index climbed 1.8% to reach a record high, marking its fourth consecutive day of gains, reflecting optimistic sentiment towards small-cap stocks likely driven by expectations of economic recovery.
- Tech Stocks Lead Gains: Micron Technology's stock surged after UBS raised its price target to $1,625, significantly boosting overall tech sector performance and reinforcing strong investor confidence in the technology industry.
- Oil Market Volatility: Despite military exchanges between the U.S. and Iran raising concerns, West Texas Intermediate crude futures fell 2.81% to $93.89 per barrel, while Brent crude rose 3.58% to $99.58, illustrating the market's complex reactions to energy prices.
See More
Co-Diagnostics Partners with Indian JV to Tackle Ebola Outbreak
- Stock Surge: Co-Diagnostics (CODX) shares soared nearly 80% on Tuesday, extending a blistering six-session rally that has seen the stock rise over 630%, reflecting strong market demand for diagnostics amid growing Ebola outbreak concerns.
- International Deployment Plan: The company is collaborating with its Indian joint venture, CoSara Diagnostics, to expedite international deployment in response to the potential global spread of the Ebola outbreak, highlighting its proactive role in emergency response efforts.
- Testing Technology Development: Co-Diagnostics is developing a PCR test targeting the Bundibugyo virus strain, with plans to introduce both Bundibugyo-specific and pan-Ebola test configurations to enhance monitoring capabilities for the outbreak.
- Global Health Emergency: The World Health Organization has declared the outbreak a public health emergency of international concern, with over 900 suspected cases and 223 suspected deaths reported, underscoring the severity of the situation and its threat to global health.
See More
